

# Global Graft Versus Host Disease (GvHD) Treatment Market 2023

<https://marketpublishers.com/r/G30CEAF60F6FEN.html>

Date: September 2023

Pages: 93

Price: US\$ 2,950.00 (Single User License)

ID: G30CEAF60F6FEN

## Abstracts

The GvHD treatment market was valued at USD 678.1 million in 2022 and is projected to reach USD 1,039 million by 2029, with a CAGR of 6.0%. GvHD occurs when the donor's T-cells attack the recipient's healthy tissues after transplant procedures. The United States had the highest number of HSCTs, followed by China and Germany. The demand for allo-HSCT is growing due to increased incidence of leukemia and lymphoma, improved transplant success rates, and an aging population.

The report covers market size and growth, segmentation, competitive landscape, trends and strategies for global GvHD treatment market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors' approaches.

### Market Segmentation

The market is segmented based on various factors, including drug class, treatment type, gender, and geography.

Drug class: calcineurin inhibitors, corticosteroids, kinase inhibitors, TNF-alpha inhibitors, others

Treatment type: acute GvHD, chronic GvHD, GvHD prophylaxis

Gender: females, males

### Segmentation by Geography

North America – US

Europe – Germany, France, UK, Italy, Spain

APAC - China, Japan

Corticosteroid drugs are projected to hold a significant share in the global GvHD treatment market, with kinase inhibitors expected to be the fastest-growing segment. Corticosteroids are commonly recommended as front-line therapy due to their safety and efficacy compared to alternative drugs. Acute GvHD is anticipated to contribute significantly to the market, affecting 30% to 50% of individuals undergoing stem cell transplantation. Males currently dominate the market, but females are projected to be the fastest-growing segment. The United States is currently dominant, but China is expected to exhibit faster growth. Factors driving the US market include increasing incidence of GvHD, presence of key players, and improved healthcare accessibility.

### Competitive Landscape

Key players in the GvHD treatment market include AltruBio, Inc., ASC Therapeutics Inc., Bristol-Myers Squibb Company, Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd., Elsalys Biotech SAS, Equillium, Inc., F. Hoffmann-La Roche AG, Genentech, Inc., GSK plc, Incyte Corporation, Janssen Global Services, LLC, Jazz Pharmaceuticals plc, JCR Pharmaceuticals Co., Ltd., Kadmon Corporation (Sanofi S.A.), MaaT Pharma SA, Mallinckrodt PLC, medac GmbH, Merck Corporation, Mesoblast Limited, MiNK Therapeutics, Inc., Neovii Pharmaceuticals AG, Novartis AG, Pharmacyclics LLC, Pluri Inc., REGiMMUNE Corporation, Sun Pharmaceutical Industries Ltd., Syndax Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Xenikos B.V., among others.

### Scope of the Report

To analyze and forecast the market size of the global GvHD treatment market.  
To classify and forecast the global GvHD treatment market based on drug class, treatment type, gender, geography.  
To identify drivers and challenges for the global GvHD treatment market.  
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global GvHD treatment market.  
To identify and analyze the profile of leading players operating in the global GvHD treatment market.

### Why Choose This Report

Gain a reliable outlook of the global GvHD treatment market forecasts from 2023 to 2029 across scenarios.  
Identify growth segments for investment.  
Stay ahead of competitors through company profiles and market data.  
The market estimate for ease of analysis across scenarios in Excel format.  
Strategy consulting and research support for three months.

Print authentication provided for the single-user license.

## Contents

### **PART 1. INTRODUCTION**

- 1.1 Description
- 1.2 Objectives of The Study
- 1.3 Market Segment
- 1.4 Years Considered for The Report
- 1.5 Currency
- 1.6 Key Target Audience

### **PART 2. RESEARCH METHODOLOGY**

- 2.1 Primary Research
- 2.2 Secondary Research

### **PART 3. EXECUTIVE SUMMARY**

### **PART 4. MARKET OVERVIEW**

- 4.1 Introduction
- 4.2 Drivers
- 4.3 Restraints

### **PART 5. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY DRUG CLASS**

- 5.1 Calcineurin inhibitors
- 5.2 Corticosteroids
- 5.3 Kinase inhibitors
- 5.4 TNF-alpha inhibitors
- 5.5 Others

### **PART 6. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY TREATMENT TYPE**

- 6.1 Acute GVHD
- 6.2 Chronic GVHD
- 6.3 GVHD prophylaxis

## **PART 7. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY GENDER**

7.1 Females

7.2 Males

## **PART 8. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY GEOGRAPHY**

8.1 North America

8.2 Europe

8.3 APAC

## **PART 9. COMPANY PROFILES**

9.1 AltruBio, Inc.

9.2 ASC Therapeutics Inc.

9.3 Bristol-Myers Squibb Company

9.4 Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd.

9.5 Elsalys Biotech SAS

9.6 Equillum, Inc.

9.7 F. Hoffmann-La Roche AG

9.8 Genentech, Inc.

9.9 GSK plc

9.10 Incyte Corporation

9.11 Janssen Global Services, LLC

9.12 Jazz Pharmaceuticals plc

9.13 JCR Pharmaceuticals Co., Ltd.

9.14 Kadmon Corporation (Sanofi S.A.)

9.15 MaaT Pharma SA

9.16 Mallinckrodt PLC

9.17 medac GmbH

9.18 Merck Corporation

9.19 Mesoblast Limited

9.20 MiNK Therapeutics, Inc.

9.21 Neovii Pharmaceuticals AG

9.22 Novartis AG

9.23 Pharmacyclics LLC

9.24 Pluri Inc.

9.25 REGiMMUNE Corporation

9.26 Sun Pharmaceutical Industries Ltd.

9.27 Syndax Pharmaceuticals, Inc.

9.28 Takeda Pharmaceutical Company Limited

9.29 Xenikos B.V.

DISCLAIMER

## I would like to order

Product name: Global Graft Versus Host Disease (GvHD) Treatment Market 2023

Product link: <https://marketpublishers.com/r/G30CEAF60F6FEN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G30CEAF60F6FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970